Wikipedia

Bare lymphocyte syndrome type II

(Redirected from Bare lymphocyte syndrome 2)

Bare lymphocyte syndrome type II (BLS II) is a rare recessive genetic condition in which a group of genes called major histocompatibility complex class II (MHC class II) are not expressed.[3][4]

Bare lymphocyte syndrome type II
Other namesHLA class 2-negative severe combined immunodeficiency, HLA Class 2-Negative
Bare lymphocyte syndrome 2 is autosomal recessive in inheritance
SpecialtyImmunology, pediatrics, endocrinology Edit this on Wikidata
SymptomsNeutropenia[1]
CausesAbsence of human leukocyte antigen class II expression [1]
Diagnostic methodGenetic test[1]
MedicationBone marrow transplant[2]

Symptoms and signs

edit

Among the signs and symptoms that Bare lymphocyte syndrome type II exhibits are the following:[1][5]

Cause

edit

The genetic cause of Bare lymphocyte syndrome type II is due to mutations in any of the following genes:[5]

  • CIITA is responsible for giving instructions to create a protein that controls transcription of genes (MHC class II), and is located at 16p13.13 (cytogenetic location),[6]
  • RFX5 has the same function(as prior gene) and is located at 1q21.3(cytogenetic location)[7]
  • RFXANK(also known as ankyrin repeat-containing regulatory factor X-associated protein) has the same function(as the other genes) and is located at 19p13.11(cytogenetic location)[8]
  • RFXAP gives information to create RFX associated protein, which also is involved in transcription of MHC class II genes, and is located at 13q13.3,(cytogenetic location)[9]

Mechanism

edit
 
MHC Class 2

Major histocompatibility complex class II proteins are important because under normal function they have important responsibility in the human body's immune system response. MHC II proteins present exogenous antigens that activate CD4+ T-lymphocytes, immune cells that are responsible for activating other immune cells like CD8+ T-lymphocytes and macrophages.[10] MHC II proteins are also important for positive and negative selection in the thymus because they present antigens to immature T-cells, allowing the T cells to differentiate into proper functioning CD4+ T-lymphocytes. This may explain why patients with BLS II display decreased levels of CD4+ T-lymphocytes in their blood.[11]

The basis for BLSII is not due to defects in the MHC II genes themselves, it is the result of mutations in genes that code for proteins, transcription factors that normally regulate the expression of the MHC II genes. One of the several proteins that are required to switch on MHC II genes in various cells types is absent. [5]

Diagnosis

edit

The diagnosis for Bare lymphocyte syndrome type II can be done via genetic testing[12] A blood test could indicate decreased CD4+ T-cells(T-helper lymphocyte), as well as serum immunoglobulin[2]

Management

edit
 
Bone marrow

In terms of treatment for major histocompatibility complex class II deficiency(Bare lymphocyte syndrome type II), one finds that according to Matheux, et al. a possible treatment for this condition might be found in cellular and gene therapy[13] The prognosis is poor (without treatment) in early childhood for this condition;[14][2] additional treatment options include anti-microbial prophylaxis prior to bone marrow transplant[2][15]

See also

edit

References

edit
  1. ^ a b c d "Bare lymphocyte syndrome 2 | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Archived from the original on 2021-03-18. Retrieved 2017-07-28.
  2. ^ a b c d al.], Stephan Strobel ... [et; Smith, Peter K. (2006). Paediatrics and Child Health the Great Ormond Street Handbook. London: Manson Pub. p. 465. ISBN 9781840765625. Retrieved 28 July 2017.
  3. ^ "OMIM Entry - # 209920 - BARE LYMPHOCYTE SYNDROME, TYPE II". omim.org. Retrieved 2017-07-13.
  4. ^ Reference, Genetics Home. "bare lymphocyte syndrome type II". Genetics Home Reference. Retrieved 2017-07-13.
  5. ^ a b c "SCID due to absent class II HLA antigens (Concept Id: C0242583) - MedGen - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-07-28.
  6. ^ Reference, Genetics Home. "CIITA gene". Genetics Home Reference. Retrieved 2017-07-28.
  7. ^ Reference, Genetics Home. "RFX5 gene". Genetics Home Reference. Retrieved 2017-07-28.
  8. ^ Reference, Genetics Home. "RFXANK gene". Genetics Home Reference. Retrieved 2017-07-28.
  9. ^ Reference, Genetics Home. "RFXAP gene". Genetics Home Reference. Retrieved 2017-07-28.
  10. ^ Reith, Walter; Picard, Capucine (2016). Major Histocompatibility Complex Class II Deficiency. Vol. 5. Academic Press. pp. 378–390. Retrieved 4 December 2020.
  11. ^ DeSandro, Angela; Nagarajan, Uma; Boss, Jeremy (September 2017). "Associations and Interactions between Bare Lymphocyte Syndrome Factors". Molecular and Cellular Biology. 20 (17): 6587–6599. doi:10.1128/mcb.20.17.6587-6599.2000. PMC 86141. PMID 10938133.
  12. ^ "Bare lymphocyte syndrome type 2, complementation group A - Conditions - GTR - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-07-28.
  13. ^ Matheux, Franck; Villard, Jean (June 2004). "Cellular and gene therapy for major histocompatibility complex class II deficiency". News in Physiological Sciences. 19 (3): 154–158. doi:10.1152/nips.01462.2003. ISSN 0886-1714. PMID 15143213.
  14. ^ RESERVED, INSERM US14 -- ALL RIGHTS. "Orphanet: Immunodeficiency by defective expression of HLA class 2". www.orpha.net. Retrieved 2017-07-28.{{cite web}}: CS1 maint: numeric names: authors list (link)
  15. ^ Bratzler, Dale W.; Dellinger, E. Patchen; Olsen, Keith M.; Perl, Trish M.; Auwaerter, Paul G.; Bolon, Maureen K.; Fish, Douglas N.; Napolitano, Lena M.; Sawyer, Robert G. (February 2013). "Clinical practice guidelines for antimicrobial prophylaxis in surgery" (PDF). Surgical Infections. 14 (1): 73–156. doi:10.1089/sur.2013.9999. hdl:2027.42/140217. ISSN 1557-8674. PMID 23461695.subscription needed

Further reading

edit
edit
 
Scholia has a topic profile for Bare lymphocyte syndrome type II.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Bare_lymphocyte_syndrome_type_II&oldid=1260378434"